Amgen’s Neulasta franchise ‘more durable’ than Street expects: Jefferies

Jefferies analyst Michael Yee notes that Mylan’s (MYL) Neulasta biosimilar Fulphila will launch in the coming weeks, which poses a risk for Amgen (AMGN), but he tells investors in a research note that “We already knew a biosimilar was coming anyway” and this news does not alter his thesis. Yee says the Street already models some Neulasta decline, which is reflected by Amgen’s multi-year low P/E multiple, and contends that, based on precedence, he thinks the Neulasta franchise might be more durable than the Street expects.

https://bit.ly/2K9OUs8